2014 Shire approved for Agrylin

October 2, 2014

Shire Japan KK announced that the Japanese MHLW (Ministry of Health, Labour and Welfare) has approved AGRYLIN® (anagrelide hydrochloride) for the treatment of essential thrombocythemia. AGRYLIN went through clinical trials in response to a request from MHLW in May 2010 based on the results of its “Study Group on Unapproved and Off-Label Drugs of High Medical Need”. AGRYLIN has been designated as an orphan drug.

Click here to read the complete press release

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe